Lyme disease.
Hayes
Edward
E
US Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000954:Antigens, Surface / Q000008:administration & dosage / Q000009:adverse effects; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage / Q000009:adverse effects; D001428:Bacterial Vaccines; D001733:Bites and Stings / Q000188:drug therapy; D006801:Humans; D008074:Lipoproteins; D008193:Lyme Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D020852:Lyme Neuroborreliosis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013987:Ticks; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein